Amyloidosis Incidence in High-Risk Cardiac Device Patients

Cardiac Amyloidosis Clinical Trial

Official title: Histopathological Incidence of Amyloidosis in High-Risk Patients Undergoing Cardiac Device Implantation

Status Recruiting

Clinical Trial Summary

This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a new, non-invasive diagnostic avenue for this condition.

Clinical Trial Description

The study targets a key gap in cardiac amyloidosis diagnosis by systematically evaluating the histopathological incidence of the disease using chest wall fat pad biopsies-tissue that is typically discarded during the implantation of cardiac devices like pacemakers, ICDs, and CRT-D/Ps. Standard surgical procedures are adhered to, ensuring minimal additional risk to patients. The collected tissue samples are analyzed by the HCA pathology laboratory to detect amyloid deposits, thereby potentially identifying amyloidosis in a non-invasive manner. In addition to the primary endpoint of histopathological diagnosis, the study retrospectively aims to validate a predictive model that incorporates a wide range of data to streamline the identification of patients at high risk for cardiac amyloidosis. Strict measures are in place to protect patient confidentiality and data security. By potentially improving diagnostic efficiency, this research could contribute to earlier detection and treatment strategies, thus improving patient outcomes for those at high risk of this life-threatening condition. ;

Related Conditions & MeSH terms

• AL Amyloidosis
• Amyloid
• Amyloidosis
• Amyloidosis Cardiac
• Cardiac Amyloidosis
• Cardiomyopathies
• Immunoglobulin Light-chain Amyloidosis
• Systemic Amyloidosis

• NCT number: NCT06186167
• Study type: Observational
• Source: Midwest Heart & Vascular Specialists
• Contact: Vasvi Singh, MD
• Phone: (913) 253-3000
• Email: vasvi.singh@hcahealthcare.com
• Status: Recruiting
• Start date: January 29, 2024
• Completion date: December 31, 2024